Fixed-dose combo of sofosbuvir and velpatasvir is approved to treat genotypes 1-6 and be the first ribavirin-free regimen for genotypes 2 and 3 of the virus.
The momentum in hepatitis C continues for Gilead Sciences Inc. as its latest single-tablet, fixed-dose combination regimen, named Epclusa,...